Floatz logo

Ensartinib

Solid Advanced Tumor

Betta Pharmaceuticals Co., Ltd.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Solid Advanced Tumor cohort.

Asset / SponsorPhaseRating
Part A: Ose-279
OSE Immunotherapeutics
Phase 1/2CCC
OSE-279
OSE Immunotherapeutics
Phase 1/2CCC
Immunoglobulin G1-kappa, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific
Betta Pharmaceuticals Co., Ltd.
Phase 1/2CCC
ose2101
OSE Immunotherapeutics
Phase 1/2CCC

Same molecule, other indications

Ensartinib is also rated in:

MPRDormant
BB
Indicative ·
65 / 100
View asset →
non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
Neoadjuvant TherapyDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →